Industry Sessions
Breakfast, 07:15-08:15
- BRS-02 | Eli Lilly | Spadolini 6
Power hour: the importance of pathologists for the success of clinical studies
001 | Lorenzo Gerratana | Welcome and introduction
002 | Lorenzo Gerratana | Introduction into clinical study management
003 | Giancarlo Pruneri | Biomarker testing in clinical trials
004 | Albrecht Stenzinger | IVDR requirements for clinical studies
005 | Lorenzo Gerratana | Q&A and Round-table discussion
006 | Albrecht Stenzinger | Summary and close - BRS-03 | Roche | Spadolini 7
Improving the diagnosis of B Cell lymphomas in routine pathology practice: advances in clonality evaluation
001 | Teresa Marafioti & Marta Cañamero | Improving the diagnosis of B Cell lymphomas in routine pathology practice: advances in clonality evaluation
Lunch, 13:00-14:30
- LS-08 | Roche Diagnostics + Johnson & Johnson | Spadolini 2
Pathways to precision: practical strategies for optimizing diagnostic excellence
001 | Angelo Paolo Dei Tos | Introduction: testing pathway and patient leakage points
002 | Deniz Nart | Precision oncology in lung cancer: enhancing patient outcomes through NGS and biomarker driven therapies – Ege University experience
003 | Sylvie Lantuejoul | Optimizing the workflow to reduce failure rates
004 | Isabelle Vanden Bempt | RNA-Based sequencing for simultaneous detection of clinically actionable fusions and mutations in solid tumours
005 | Angelo Paolo Dei Tos | Round table and Q&A - LS-09 | AstraZeneca | Spadolini 3
Exploring the expanding applications of ctDNA and pathway mutations in breast cancer diagnostics
001 | Espen Walker | Welcome and introduction
002 | Elena Guerini Rocco | The utility of ctDNA in breast cancer
003 | Nicola Fusco | Emerging testing strategies for the optimization of patient profiling in HR+/HER2- breast cancer
004 | Espen Walker | Closing remarks - LS-10 | 3DHistech | Spadolini 4
Digital Pathology, IHC and Cytology
001 | Catarina Eloy | Postponing evolution: why are we choosing to ignore the need for a digital transformation in pathology?
002 | Felix Offner | Experiences with the implementation of digital cytology with Datexim and 3DHistech in Feldkirch, Austria
003 | Yukako Yagi | Digital IHC, digital microCT - LS-11 | gsk | Spadolini 5
Guiding clinical outcomes in gynaecological cancers with early and accurate biomarker testing, including case-based examples
001 | Gian Franco Zannoni | Introduction to biomarker testing in gynaecological cancers
002 | Josef Rüschoff | Biomarker testing in endometrial cancer: current status and key considerations
003 | Vanda Salutari | Treatment options according to molecular classification in endometrial cancer: clinical perspective and case study
004 | Gian Franco Zannoni | Panel discussion on biomarker testing in endometrial cancer
005 | Isabelle Treilleux | Biomarker testing in ovarian cancer: focus on HRD and BRCA
006 | Vanda Salutari | Impact of biomarker testing on patient outcomes in ovarian cancer: clinical perspective and case study
007 | Gian Franco Zannoni | Panel discussion on biomarker testing in ovarian cancer - LS-12 | Agilent Technologies | Spadolini 7
Changing testing in gastric cancer: a practical review
001 | Mar Iglesias | Welcome & focus
002 | Manuel Rodriguez-Justo | Case 1: The critical role of preanalytics in the context of case referrals
003 | Matteo Fassan | Case 2: Assessing case heterogeneity effectively: from number of biopsies to tumour staging
004 | Mar Iglesias | Q&A and closing remarks
Lunch, 13:00-14:30
- LS-13 | Roche | Spadolini 2
Precision diagnostics in ovarian cancer: traversing from testing to treatment
001 | Michelle Shiller & Domenica Lorusso - LS-14 | AstraZeneca | Spadolini 3
NSCLC: the evolution and expansion of testing across the care continuum
001 | Alexander Yarunin | Welcome and introduction
002 | Giuseppe Perrone | Navigating the evolving NSCLC testing landscape: guidance for the detection of driver and acquired resistance mutations
003 | Nicola Normanno | Plasma ctDNA testing in lung cancer: application across the care continuum
004 | Elena Guerini Rocco | Evaluating pathological complete response
005 | Alexander Yarunin | Closing remarks - LS-15 | Astellas | Spadolini 4
The Pathologist’s loom: weaving CLDN18.2 into practice
001 | Matteo Fassan | Welcome and introductions
002 | Lorenzo Fornaro | Unravelling the gastric cancer and GEJ tapestry: clinical insights into the current treatment landscape and emerging biomarkers
003 | Philippe Taniere | Stitching the narrative: CLDN18.2 in the fabric of G/GEJ adenocarcinoma
004 | Matteo Fassan | The Pathologist’s canvas: exploring CLDN18.2 expression patterns in G/GEJ adenocarcinoma
005 | Matteo Fassan | Q&A session
006 | Matteo Fassan | Summary and close
HotSpots
- Siemens Healthineers AG | 9 September 2024, 09:30-09:50, HotSpot stage at exhibition area
Navigating the galaxy of data: a journey through digital pathology
Dr. Svenja Lippok, Germany
- SOPHiA GENETICS | 9 September 2024, 10:00-10:20, HotSpot stage at exhibition area
Building evidence and confidence in liquid biopsy solutions
Dr. Alexander Yarunin, United Kingdom
Verena Schramm, Germany - SOPHiA GENETICS | 10 September 2024, 09:30-09:50, HotSpot stage at exhibition area
Insights with impact: empowering laboratories with robust CGP solutions
Verena Schramm, Germany - Sysmex Europe SE | 10 September 2024, 10:00-10:20, HotSpot stage at exhibition area
Liquid biopsy in breast cancer patient care
Maria De Bonis, Italy
Prof. Angelo Minucci, Italy
Meet-the-Expert
Roche (booth no. 15) will offer 6 Meet-the-Expert talks during the follwing times:
- Sunday, Sep 8, 13:10 – 13:30
PIK3CA; Leveraging emerging insights to drive personalised care
Dr. Nicola Fusco, Italy - Sunday, Sep 8, 14:00-14:20
The Roche Digital LightCycler: a real world performance evaluation in a Dutch hospital laboratory
Dr. Wouter Pattje, USA - Monday, Sep 9, 14:00-14:20
Advancing precision medicine: PathAI and Roche Collaborate for AI-powered companion diagnostics
Eric Walk, USA
Michael Rivers, USA - Monday, Sep 9, 13:10- 13:30
Seamless integration of Ibex’s AI algorithms within Roche’s navify® Digital Pathology
Michael Rivers, USA
Stuart Shand, The Netherlands - Monday, Sep 9, 16:40 – 17:00
Unlock the power of in-house comprehensive genomic profiling with AVENIO Tumor Tissue CGP Kit V2 and the new foundation medicine HRD signature
Robert Bulte, Switzerland
Muriel De Vos, Switzerland - Tuesday, Sep 10, 13:10 – 13:30
Gastric cancer testing landscape in 2024 and beyond
Mar Iglesias, Spain